Summary The concentrations of the soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) were investigated in 45 patients with gastric cancer before treatment and their correlation with clinical, histological and routine laboratory parameters was examined. Data were collected on tumour stage at presentation, presence and sites of metastatic disease, tumour pathology, survival and results of routine laboratory tests. Serum concentrations of ICAM-1 and VCAM-1 were significantly elevated in the patients with gastric cancer in comparison with the group of healthy subjects (P < 0.00001 and P < 0.0001 respectively). Increased serum concentrations of VCAM-1 were associated with locally advanced and metastatic disease whereas ICAM-1 was significantly elevated both in local and in advanced/metastatic disease. Soluble E-cadherin and E-selectin concentrations did not show any significant elevation in gastric cancer patients. Concentrations of soluble adhesion molecules showed significant correlation with each other (except E-selectin and VCAM-1) and with alkaline phosphatase. Soluble ICAM-1 and VCAM-1 were significantly associated with an elevated total white cell count. Patients with elevated VCAM-1 had significantly poorer survival in comparison with patients with normal serum levels (P= 0.0361).
(ICAM-1); vascular cell adhesion molecule-1 (VCAM-1); adhesion Intercellular adhesion molecule-I (ICAM-1) and vascular cell adhesion molecule-I (VCAM-1) are cytokine-inducible glycoproteins belonging to the immunoglobulin supergene family. ICAM-I is expressed constitutively but weakly on leucocytes, endothelial cells and antigen-presenting cells such as Langerhans cells, whereas VCAM-1 has a more restricted distribution, being found predominantly on activated endothelial cells but also on dendritic cells and renal proximal tubule cells. Both are up-regulated by inflammatory cytokines such as interleukin 1 (IL-1), tumour necrosis factor alpha (TNF-a) and interferon-gamma (Katz et al, 1991; Carlos and Harlan, 1994) . Both ICAM-l and VCAM-l are predominantly involved in leucocyte-endothelial cell adhesion, with their ligands being LFA-l and Mac-I (ICAM-1) and VLA-4 (VCAM-1), and are implicated in the progression of malignant melanoma and myeloid malignancies (Harning et al, 1991; Giavazzi et al, 1992; Srivastava et al, 1994; Albelda et al, 1990; Staunton et al, 1990 ; Molica et al, 1995) possibly by mediating tumour cell-endothelial cell interactions.
Selectins are transmembrane glycoproteins that contain a lectinlike domain, epidermal growth factor-like motif and a series of consensus repeats similar to those in complement regulatory proteins and mediate cell-cell contact through Ca2+-dependent interactions with cell-surface carbohydrates. Endothelial selectin (E-selectin) is expressed on cytokine-activated endothelium and initiates rolling of leucocytes. This is followed by firm adhesion through integrin-dependent recognition of Ig-like receptors on the (McEver, 1994; Smith et al, 1995; Suzuki et al, 1995) .
Recently soluble forms of several adhesion molecules including ICAM-1, VCAM-1 and E-selectin have been described . In patients with cancer, high levels of circulating ICAM-1 have been found to be associated with the presence of liver metastases in gastric, colonic, gall bladder and pancreatic cancer (Tsujisaki et al, 1991) , with poor survival of patients with malignant melanoma (Harning et al, 1991; Altomonte et al, 1992; Kageshita et al, 1992 Kageshita et al, , 1993 Viac et al, 1993) and correlated with disease stage and progression in Hodgkin's disease (Gruss et al, 1993) . Soluble forms of E-cadherin have been identified in serum and urine of normal individuals and patients with cancer and cutaneous diseases (Katayama et al, 1994b; Banks et al, 1995; Matsuyoshi et al, 1995) .
After preliminary observations of elevated soluble ICAM-1, VCAM-1, and E-selectin concentrations in patients with a heterogeneous group of advanced cancers (Banks et al, 1993) , we now report the results of a study investigating the concentration of circulating forms of adhesion molecules E-cadherin, ICAM-1, VCAM-1 and E-selectin in patients with gastric cancer before treatment and their correlation with clinical, histological and routine laboratory parameters. (Fielding et al, 1984 
Assay of soluble adhesion molecules
Venous blood samples were collected into plain tubes, allowed to clot and within 1 h of collection were centrifuged at 800 g for 10 min. The serum was removed, aliquoted and stored at -70°C until assayed. Concentrations of soluble ICAM-1, VCAM-1, E-selection and E-cadherin were measured with commercially available sandwich ELISA kits based on dual monoclonal antibodies (R & D Systems Europe, Abingdon, UK for ICAM-1, VCAM-1 and E-selectin; Takara Shuzo Co, Otsu, Japan for E-cadherin), according to the manufacturers' protocols.
Statistical analysis
Data were analysed using SPSS and SAS. Results were not normally distributed and accordingly were analysed using nonparametric tests. Comparisons of the level of soluble adhesion molecules in gastric cancer patients and healthy subjects were performed using the Mann-Whitney U-test. A correlation matrix of the levels of soluble adhesion molecules and the clinical, British Journal of Cancer (1997) pathological and laboratory parameters was calculated using the Spearman rank correlation method. Survival curves were calculated according to the Kaplan-Meier method and compared using the two-sided log-rank test.
RESULTS
Concentrations of soluble E-cadherin, E-selectin, ICAM-1 and VCAM-1 in the control and patient groups are shown in Fig. 1 (A-D) and Table 2 . Elevated soluble adhesion molecule levels were defined as greater than the 95th percentile in healthy subjects. In some patients, soluble ICAM-1 and VCAM-1 concentrations were found to be above the normal range and were significantly elevated (median values 311.0 ng ml-', range 114.0-1617.0 ng ml-', P < 0.00001 and median value 870.0 ng ml-', range 444.0-8648.0 ng ml-', P < 0.0001) in comparison with the healthy subjects. The concentrations of soluble E-cadherin and E-selectin did not show significant elevation in gastric cancer patients (median values 3.19 ng ml-', range 1.07-12.04 ng ml-', P = 0.92, and 38.0 ng ml-', range 15.0-178.0 ng ml-', P = 0.54, respectively) although a few patients had high concentrations.
There was a significant difference between the median serum concentrations of ICAM-1 and VCAM-1 of patients with stage III and IV disease (i.e. with lymph node and distant metastases) and normal subjects (P <0.00001), as well as between the serum concentration of ICAM-1 of patients with stage I and II disease and normal subjects (P = 0.036). There was no difference between the median serum concentration of VCAM-1 of patients with stage I and H gastric cancer and healthy control subjects (P = 0.134). The difference between the median serum concentration of VCAM-1 in patients with stage I and II gastric cancer and stage III and IV did not reach statistical significance (P = 0.134) (Figure 2A and B) .
The levels of circulating soluble adhesion molecules were found to be significantly correlated with each other, with the exception of E-Selectin and VCAM-1. The correlation matrix is shown in Table 3 .
To determine whether the concentration of soluble adhesion molecules is influenced by tumour Control subjects which only biopsies were available, it was not possible to assess the degree of ulceration and differentiation. We compared the serum concentrations of soluble adhesion molecules for the different groups of tumours based on their pathology grading including the group with missing data as a separate group. The median serum concentrations of adhesion molecules in the group with missing pathology (which by definition were more likely to be those with more advanced and unresectable disease) were similar to the high-grade tumours with a trend to be higher than concentrations for low-grade tumours but the difference did not reach statistical significance (data not shown).
A significant correlation was found between the serum concentrations of all soluble adhesion molecules and alkaline phosphatase. Nine patients had elevated alkaline phosphatase -four of them had documented liver metastases and five had locally advanced cancer; three had elevated levels of soluble E-cadherin, three of E-selectin, seven of ICAM-1 and eight of VCAM-1. Out of six patients with diagnosed liver metastasis, four had elevated serum concentrations of VCAM-1. ICAM-1 and VCAM-1 were positively correlated with the total white cell count and negatively with the serum albumin. A similar association with serum albumin was found for E-cadherin, which was also negatively associated with haemoglobin concentration and positively with serum levels of CEA and platelet count (Table 4) .
Survival of those patients with normal and elevated levels of each of the soluble adhesion molecules was compared using the log-rank test. Only those patients with elevated VCAM-I showed a significantly poorer survival than those with normal levels, as illustrated in Figure 3 (%2 = 4.4, P = 0.036). The small number of patients meant it was not possible to carry out a full multivariate survival analysis to determine whether elevated levels of any of the soluble adhesion molecules are independent predictors of survival. However, as clinical stage is associated with both poorer survival (Fig. 4) and elevated levels of VCAM-I and ICAM-1, the effect of elevated soluble adhesion molecules was tested, after allowing for clinical stage, using a stratified log-rank test. This gave a significant result for elevated VCAM-1 (X2 = 7.5, P = 0.0006) and a nonsignificant result for ICAM-1 (%2 = 2.5, P = 0.111).
It is possible that the results could be explained by differences in prognostic variables not taken into account in this analysis. These advanced and metastatic disease, whereas si are significantly elevated both in local ar disease. Circulating ICAM-1 has been found to be associated with liver metastases in gastrointestinal cancer (Tsujisaki et al, 1991) , with disease stage, progression and survival of patients with malignant melanoma (Harning et al, 1991; Altomonte, 1992; Kageshita et al, 1992 Kageshita et al, , 1993 Viac et al, 1993 ) and Hodgkin's disease (Gruss et al, 1993) . Our study extends and confirms these observations for patients with gastric cancer and also for the first time reports elevated serum levels of VCAM-1 in gastric cancer. In addition, we have found that patients with elevated serum VCAM-1 have poorer survival than patients with normal levels using univariate stratified survival analysis. This result suggests that the measurement of circulating VCAM-1 and possibly ICAM-1 may bring additional prognostic information for patients with gastric cancer different from stage and tumour pathology and they should be included in future large, multivariate analyses of prognostic factors whenever possible. The association of elevated soluble adhesion molecules with 40 50 60 raised alkaline phosphatase and decreased serum albumin may tatment explain the mechanism of their elevation. A series of reports has shown elevated serum concentrations of ICAM-1, VCAM-1 and iccording to serum levels of E-selectin in patients with liver diseases, including chronic .levated hepatitis, liver cirrhosis, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease and hepatocellular carcinoma (Adams et al, 1992 (Adams et al, , 1994 Hyodo et al, 1993; Fabris et al, 1994; Pirisi et al, 1994; Garcia-Barcina et al, 1995; Lim et al, 1995) . This elevation may result from lymphocyte activation. However, E-selectin and ICAM-1 are more elevated in cholestatic liver disease (primary biliary cirrhosis and primary sclerosing cholangitis) than in other liver diseases found that soluble ICAM-1 levels correlate with serum bilirubin and alkaline phosphatase. Thus, cholestasis may be a major factor influencing circulating ICAM-1. This has been further confirmed by the finding that, in addition to inflammation, cholestasis and decline of functional hepatic mass may influence ICAM-1 concentration . One possible explanation of our results would be that soluble adhesion molecules have a biliary route of excretion and their clearance is impaired in the presence of intrahepatic cholestasis secondary to liver metastases. Their association with survival is therefore more likely to be related to the location of metastatic disease rather than underlying tumour biology.
Not all patients with elevated ICAM-1 and VCAM-1 had 40 50 60 elevated alkaline phosphatase and so the increase might be multifactorial in origin. The correlation of soluble ICAM-1 and VCAMeatment 1 with total white cell count suggests a role for inflammatory reactions. The expression of both ICAM-1 and VCAM-1 on y stage of disease endothelial cells is known to be rapidly up-regulated by inflammatory cytokines and there are reports of increased serum levels of interleukin 1 and interleukin 6 in patients with gastric cancer (Kabir et al, 1995; Wu et al, 1996) . It has been shown that stimulation of cultured normal human hepatocytes with proinflammatory r investigation into the cytokines induces cell-surface expression of ICAM-1 and secres prognostic markers.
tion/shedding of soluble ICAM-1 into the hepatocyte culture medium (Thomson et al, 1994) . Enhanced ICAM-1 expression has been found on cell membranes of hepatocellular cancer and the possibility of its shedding into the circulation has been suggested trations of ICAM-1 and (Hyodo et al, 1993; Torii et al, 1993) . Soluble ICAM-1 has been -nts with gastric cancer implicated as a marker of prognosis and disease progression in observed that elevated hepatocellular carcinoma (Shimizu et al, 1995) . Koyama (Shino et al, 1991 (Shino et al, , 1995 Mayer et al, 1993) . The role of circulating forms of E-cadherin is less clear but Katayama et al (1994a) reported significantly elevated soluble E-cadherin molecules in 22 patients with gastric cancer, and it is conceivable that shedding may contribute to the reduced cellular expression. However, the lack of correlation with stage and histological grade of the tumours would not support this. It is worth noting the correlation of Ecadherin with CEA as both are epithelial cell adhesion molecules. CEA, which has been clinically used for some time as a serum marker of tumour burden in patients with gastrointestinal cancer, has also recently been shown to function as homotypic Ca2+-independent intercellular adhesion molecule (Hostetter et al, 1990; Zhou et al, 1993a Zhou et al, , 1993b . In our study, CEA performed better as a marker of the tumour burden and prognosis than E-cadherin (data not shown) and it does not seem that soluble E-cadherin could have any clinical significance similar to that of CEA in patients with gastric cancer.
E-selectin has been implicated in the adhesion of colorectal and gastric cancer cells expressing sLex to activated endothelial cells (Maehara et al, 1993) . Serum levels of E-selectin have been found to be significantly elevated in patients with metastatic liver lesions from colorectal cancer in comparison with patients with no metastases (Wittig et al, 1996) . Our findings do not support the suggestion that serum levels of E-selectin may be of importance for monitoring tumour progression in gastric cancer.
A number of studies in a variety of malignant diseases suggest a role for ICAM-1 in the process of tumour growth and metastasis. VCAM-1 is also emerging as an important adhesion molecule in malignancy. In our group of gastric cancer patients, the concentrations of circulating ICAM-1 and VCAM-1 were associated with advanced and metastatic disease and had prognostic significance. Further longitudinal studies in large numbers of cancer patients with measurement of circulating ICAM-1 and VCAM-1 during the course of the disease and during active treatment are needed in order to define the emerging clinical significance of these molecules. ACKNOWLEDGEMENT GV, REB, MAF, MJ, JA-M and PJS. are grateful to the Imperial Cancer Research Fund for financial support.
